Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Administration Of TGF-beta Resistant Cytotoxic T-Lymphocytes to Patients With EBV-positive Nasopharyngeal Carcinoma (RESIST-NPC)

NCT02065362 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT02065362
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02065362 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Administration Of TGF-beta Resistant Cytotoxic T-Lymphocytes to Patients With EBV-positive Nasopharyngeal Carcinoma (RESIST-NPC)
Lead sponsor
Baylor College of Medicine
Phase
Phase 1
Overall status
Active, not recruiting
Start date
February 28, 2015
Completion date
February 28, 2033
Enrollment
14 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ebv-positive nasopharyngeal carcinoma